Ivermectin clinical trials
Ivermectin is named as an intervention in 3 current clinical trials in our Ireland, India, Germany, France, Spain, Italy, Netherlands, Belgium, Switzerland, Czechia, Portugal, Canada, Japan, Australia, Israel, Brazil and Egypt registers. 3 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is UMC Utrecht (1). The most-studied condition is Respiratory Tract Diseases.
Where Ivermectin is approved
All regulators →Of the three regulators tracked here, the first to approve Ivermectin was the US, on 22 Nov 1996. It is approved in 2 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Ivermectin patents and exclusivity
Expiry tracker →Protections still running for marketed products containing Ivermectin, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
- 5 listed patents; the last listed expires 13 Mar 2034 (US 9233118).
Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
What health systems spend on Ivermectin
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Ivermectin works
All drug targets →- Glutamate-gated chloride channel modulator ModulatorChEMBL only
- COVID-19Phase 3
- AscariasisPhase 3
- BlepharitisPhase 3
- Filarial elephantiasisPhase 3
- Hookworm infectious diseasePhase 3
- Inclusion conjunctivitisPhase 3
- Ocular onchocerciasisPhase 3
- PneumoniaPhase 3
- TrichuriasisPhase 3
- YawsPhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL6067487, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 2373, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Ivermectin
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 3 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Ivermectin
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
NCT02735707 · Respiratory Tract Diseases, Influenza (Pandemic), Influenza
|
Phase 3 | Recruiting | UMC Utrecht | Ireland, India, Germany, France, Spain, Italy, Netherlands, Belgium, Switzerland, Czechia, Portugal, Canada, Japan, Australia, Israel |
|
The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment
NCT04351347 · ClinicalTrials.gov ↗ · COVID
|
Phase 2/3 | Recruiting | Tanta University | Egypt |
|
Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)
NCT05041907 · ClinicalTrials.gov ↗ · COVID-19
|
Phase 2 | Recruiting | University of Oxford | Brazil |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Ivermectin across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
3 single-substance products containing Ivermectin on the HPRA medicines list.
- Iverscab 3 mg tabletsSubstipharm · PA1677/008/001 · Marketed
- Soolantra 10 mg/g CreamGalderma International · PA22743/015/001 · Marketed
- Soolantra 10 mg/g CreamIMED Healthcare Ltd. · PPA1463/247/001
Supply shortages
- Ivermectin TabletUS (FDA) · Resolved · updated 29 Sep 2026
- DRIPONIN 3 mg TablettenGermany (BfArM) · Other reason · 28 Nov 2025 to 14 Dec 2026
Conditions studied with Ivermectin
6 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| UMC Utrecht | 1 |
| University of Oxford | 1 |
| Tanta University | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Ivermectin trials
How many clinical trials are testing Ivermectin?
3 current trials in our Ireland, India, Germany, France, Spain, Italy, Netherlands, Belgium, Switzerland, Czechia, Portugal, Canada, Japan, Australia, Israel, Brazil and Egypt registers name Ivermectin as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Ivermectin trials recruiting patients?
Yes. 3 of the 3 trials are recruiting: 1 with sites in Ireland, 1 with sites in India, 1 with sites in Germany, 1 with sites in France, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in Netherlands, 1 with sites in Belgium, 1 with sites in Switzerland, 1 with sites in Czechia, 1 with sites in Portugal, 1 with sites in Canada, 1 with sites in Japan, 1 with sites in Australia, 1 with sites in Israel, 1 with sites in Brazil and 1 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Ivermectin clinical trials?
UMC Utrecht (1), University of Oxford (1) and Tanta University (1). The number in brackets is how many trials each organisation leads.
Are there Ivermectin clinical trials in Ireland?
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Is Ivermectin licensed in Ireland?
Yes. The HPRA medicines list includes 3 single-substance products containing Ivermectin, for example Iverscab 3 mg tablets (Substipharm). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Ivermectin shortage?
The registers we track list 2 entries for Ivermectin: US FDA: resolved; 1 German notice. Shortages are product- and country-specific; check with a pharmacist.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Ivermectin works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Ivermectin works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Ivermectin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.